详情请进入 湖南阳光电子学校 已关注:人 咨询电话:0731-85579057 微信号:yp941688, yp94168
Results press release will be issued at: 12:00 GMT / 07:00 ET Investor meeting and conference call time: 14:30 GMT / 09:30 ET
Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:30 GMT/9:30 ET.
Please RSVP ssalah@shire.com (T: +44(0)1256-894-160) for this conference call.
The details of the conference call are as follows: UK dial in: +44(0)800-953-0810, US dial in: +1-866-789-2220, International dial in: +44(0)1452-560-068, Password/Conf ID: 20443623# Live Webcast:* ?tn=2&m1=33
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:
UK dial in: +44(0)800-953-1533, US dial in: +1-866-247-4222, International dial in: +44(0)1452-55-00-00, Pin code: 20443623# Webcast replay:* ?tn=2&m1=33 * Email verification is required Notes to editors Shire PLC
Shire''s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire''s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company''s website:
Source: Shire PLC
(整理:润州PLC编程培训学校)
湖南阳光电子学校教学特色